Oppenheimer Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with an Outperform rating and a price target of $50.
June 04, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Cartesian Therapeutics with an Outperform rating and a price target of $50, indicating strong potential for growth.
The initiation of coverage with an Outperform rating and a high price target by a reputable analyst can boost investor confidence and likely lead to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100